Technical Seminar: Diverse Applications of mRNA-LNP Technology
Diverse Applications of mRNA-LNP Technology - Register here!
Date: March 27, 2024
Time: 8:30 - 11:30 AM ET
Location: McGill Engine Centre (FDA 5)
Kindly note that the seats are limited and the priority registration will be given to McGill RNA community. We will confirm successful registrations by email prior to the seminar.
Speakers:
Dr. Nedim Emil Altaras is the current leader of Technical Development at Moderna, where he has a distinguished track record that spans over 20 years in the field of vaccines and biologics. He has played key roles in overseeing Global Product, Development, Manufacturing, Supply Chain, and Operations teams. His roles at Moderna have included Head of External Manufacturing and CMC Vaccines lead.
Prior to his current role, Dr. Altaras was responsible for setting up the manufacturing operations at Seres Therapeutics, which focused on the production of new live biologics for microbiome therapeutics. His career commenced at Merck & Co., Inc. in Bioprocess R&D, where he supported the development of various early-stage vaccine candidates. He held several significant positions during his tenure at Merck, leading the Fermentation and Cell Culture Development and overseeing development teams for multiple vaccine programs. Later, he moved into the Manufacturing division, where he established the value-chain management for various vaccine products and led the creation of manufacturing and supply chain operations for a partnership product.
Dr. Altaras's educational background includes a Bachelor of Engineering from McGill University, awarded in 1994, and a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, completed in 1999. He also holds a Master's degree in Organizational Dynamics from the University of Pennsylvania, obtained in 2014.
Dr. Amy Rabideau is a Fellow and the Technical Lead for Early Development at Moderna. In this role, she leads a cross functional team focused on defining and characterizing the processes used to manufacture the products advancing into the clinic. Amy previously led the Early Phase mRNA process development team at Moderna, responsible for defining and implementing mRNA processes for Moderna’s Early Phase portfolio. She led a team of scientists and engineers in advancing our understanding of RNA process development, characterizing the product and process related impurities, and devising production strategies to reduce immunostimulatory impurity formation, including engineering T7 RNA polymerases. Prior to her 8.5 year tenure at Moderna, Amy completed her PhD in Biological Chemistry at MIT and her BS in Chemistry and Biology at Syracuse University.
